StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
16
Publishing Date
2023 - 11 - 07
1
2023 - 07 - 26
1
2023 - 05 - 09
1
2023 - 04 - 04
1
2023 - 03 - 15
1
2023 - 03 - 08
1
2023 - 02 - 16
1
2023 - 01 - 24
1
2023 - 01 - 09
1
2022 - 10 - 13
1
2022 - 08 - 25
1
2022 - 07 - 06
1
2022 - 06 - 22
1
2022 - 06 - 02
1
2022 - 04 - 27
1
2021 - 12 - 13
1
Sector
Health technology
16
Tags
Agreement
1
Alzheimer
1
Alzheimer's
1
Alzheimer’s
3
Animal
1
Application
1
Approval
1
Ath434
22
Australia
2
Authorization
4
Biomarker
1
Conference
3
Congress
1
Disease
8
Disorders
1
Drug
2
Europe
2
Fda
1
Flow
8
Fy22
3
Fy23
4
Fy24
2
Global
1
Grant
1
Granted
2
House
1
International
2
Key
1
License
1
Life
1
Meeting
6
Million
1
Mst
1
N/a
65
Natural
3
Neurodegenerative
2
Neurological
1
Neurology
1
Order
1
Parkinson
2
Parkinson’s
6
Patent
4
Phase 2
16
Pipeline
1
Positive
1
Presentation
7
Rare
4
Report
9
Research
2
Sciences
1
Sensor
3
Study
7
System
15
Therapeutics
49
Train
1
Treatment
6
Trial
16
Usa
1
Week
1
World
1
Entities
Alterity therapeutics limited
16
Symbols
ATHE
16
Exchanges
Nasdaq
16
Crawled Date
2023 - 11 - 08
1
2023 - 07 - 26
1
2023 - 05 - 10
1
2023 - 04 - 04
1
2023 - 03 - 16
1
2023 - 03 - 08
1
2023 - 02 - 16
1
2023 - 01 - 24
1
2023 - 01 - 09
1
2022 - 10 - 13
1
2022 - 08 - 25
1
2022 - 07 - 06
1
2022 - 06 - 23
1
2022 - 06 - 02
1
2022 - 04 - 27
1
2022 - 01 - 06
1
Crawled Time
00:00
5
01:00
3
02:00
2
03:00
3
04:00
1
13:27
1
23:00
1
Source
alteritytherapeutics.com
16
alzamend.com
3
contravir.com
5
firstcobalt.com
4
investor.assemblybio.com
3
investors.biomarin.com
2
ir.akerotx.com
2
ir.anaptysbio.com
2
ir.auriniapharma.com
2
ir.benitec.com
2
ir.biolinerx.com
6
ir.hoththerapeutics.com
5
ir.kalvista.com
3
ir.opgen.com
2
ir.radiuspharm.com
3
ir.vaccinex.com
2
ir.viveve.com
6
ir.zynerba.com
2
jaguarhealth.gcs-web.com
5
mindmed.co
6
neurosense.investorroom.com
6
ocutx.gcs-web.com
3
renovorx.com
2
spacfeed.com
9
velodynelidar.com
9
www.4dpharmaplc.com
6
www.achievelifesciences.com
5
www.adnas.com
4
www.agtc.com
5
www.akerotx.com
3
www.allogene.com
2
www.anaptysbio.com
3
www.anavex.com
4
www.aquestive.com
3
www.athira.com
3
www.atyrpharma.com
3
www.balchem.com
2
www.biolase.com
2
www.biospace.com
2756
www.brainsway.com
3
www.celyad.com
3
www.chi-med.com
2
www.daxor.com
2
www.fatetherapeutics.com
6
www.fda.gov
7
www.fsdpharma.com
5
www.globenewswire.com
2281
www.hancockjaffe.com
3
www.igcinc.us
6
www.inovio.com
8
www.inventivapharma.com
5
www.nantkwest.com
7
www.novocure.com
5
www.nurixtx.com
5
www.ppdi.com
4
www.prnewswire.com
1442
www.stagindustrial.com
21
www.veeva.com
3
www.vynetherapeutics.com
4
www.zynerba.com
3
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Trial
source :
Alteritytherapeutics.com
save search
Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy
Published:
2023-11-07
(Crawled : 00:00)
- alteritytherapeutics.com
ATHE
|
$2.04
-4.67%
-4.9%
54K
|
Health Technology
|
-13.19%
|
O:
5.96%
H:
8.43%
C:
6.43%
ath434
system
trial
therapeutics
phase 2
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned
Published:
2023-07-26
(Crawled : 00:00)
- alteritytherapeutics.com
ATHE
|
$2.04
-4.67%
-4.9%
54K
|
Health Technology
|
-26.35%
|
O:
2.89%
H:
5.8%
C:
3.5%
trial
therapeutics
phase 2
Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy
Published:
2023-05-09
(Crawled : 00:00)
- alteritytherapeutics.com
ATHE
|
$2.04
-4.67%
-4.9%
54K
|
Health Technology
|
-29.66%
|
O:
0.34%
H:
0.0%
C:
-1.71%
ath434
australia
global
system
trial
therapeutics
phase 2
Alterity Therapeutics Enrols First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
Published:
2023-04-04
(Crawled : 02:00)
- alteritytherapeutics.com
ATHE
|
$2.04
-4.67%
-4.9%
54K
|
Health Technology
|
-25.82%
|
O:
-1.73%
H:
3.61%
C:
3.61%
ath434
system
trial
therapeutics
phase 2
Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
Published:
2023-03-15
(Crawled : 00:00)
- alteritytherapeutics.com
ATHE
|
$2.04
-4.67%
-4.9%
54K
|
Health Technology
|
-21.84%
|
O:
7.28%
H:
5.0%
C:
-0.54%
ath434
system
trial
therapeutics
phase 2
Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
Published:
2023-03-08
(Crawled : 04:00)
- alteritytherapeutics.com
ATHE
|
$2.04
-4.67%
-4.9%
54K
|
Health Technology
|
-37.23%
|
O:
2.49%
H:
0.57%
C:
-0.92%
ath434
system
trial
therapeutics
phase 2
Alterity Therapeutics Receives Regulatory Authorization in France and Austria to Proceed with ATH434 Phase 2 Clinical Trial
Published:
2023-02-16
(Crawled : 02:00)
- alteritytherapeutics.com
ATHE
|
$2.04
-4.67%
-4.9%
54K
|
Health Technology
|
-32.23%
|
O:
4.65%
H:
3.81%
C:
2.86%
ath434
trial
therapeutics
authorization
phase 2
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy
Published:
2023-01-24
(Crawled : 23:00)
- alteritytherapeutics.com
ATHE
|
$2.04
-4.67%
-4.9%
54K
|
Health Technology
|
-47.42%
|
O:
-2.06%
H:
5.66%
C:
2.63%
ath434
treatment
system
trial
therapeutics
phase 2
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy
Published:
2023-01-09
(Crawled : 03:00)
- alteritytherapeutics.com
ATHE
|
$2.04
-4.67%
-4.9%
54K
|
Health Technology
|
-41.7%
|
O:
1.46%
H:
2.22%
C:
-2.82%
ath434
treatment
system
trial
therapeutics
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy
Published:
2022-10-13
(Crawled : 03:00)
- alteritytherapeutics.com
ATHE
|
$2.04
-4.67%
-4.9%
54K
|
Health Technology
|
-54.75%
|
O:
-4.1%
H:
6.41%
C:
6.34%
ath434
treatment
system
australia
trial
therapeutics
phase 2
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe
Published:
2022-08-25
(Crawled : 01:00)
- alteritytherapeutics.com
ATHE
|
$2.04
-4.67%
-4.9%
54K
|
Health Technology
|
-66.23%
|
O:
1.9%
H:
8.85%
C:
-3.17%
ath434
treatment
europe
system
trial
therapeutics
phase 2
Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
Published:
2022-07-06
(Crawled : 01:00)
- alteritytherapeutics.com
ATHE
|
$2.04
-4.67%
-4.9%
54K
|
Health Technology
|
-67.3%
|
O:
-2.17%
H:
11.64%
C:
1.84%
ath434
system
trial
therapeutics
phase 2
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy
Published:
2022-06-22
(Crawled : 00:00)
- alteritytherapeutics.com
ATHE
|
$2.04
-4.67%
-4.9%
54K
|
Health Technology
|
-66.41%
|
O:
0.43%
H:
9.84%
C:
4.79%
ath434
trial
therapeutics
authorization
phase 2
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy
Published:
2022-06-02
(Crawled : 01:00)
- alteritytherapeutics.com
ATHE
|
$2.04
-4.67%
-4.9%
54K
|
Health Technology
|
-70.43%
|
O:
-2.9%
H:
11.93%
C:
7.84%
ath434
treatment
system
trial
therapeutics
phase 2
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom
Published:
2022-04-27
(Crawled : 03:00)
- alteritytherapeutics.com
ATHE
|
$2.04
-4.67%
-4.9%
54K
|
Health Technology
|
-72.98%
|
O:
0.7%
H:
2.6%
C:
-2.0%
ath434
trial
therapeutics
authorization
phase 2
First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial
Published:
2021-12-13
(Crawled : 13:27)
- alteritytherapeutics.com
ATHE
|
$2.04
-4.67%
-4.9%
54K
|
Health Technology
|
-77.06%
|
O:
0.24%
H:
3.2%
C:
0.42%
ath434
phase 2
trial
authorization
Gainers vs Losers
67%
33%
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.